Traynor Capital Management’s Direxion Daily S&P Biotech Bull 3X ETF LABU Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-8,586
| Closed | -$773K | – | 290 |
|
|
2024
Q4 | $773K | Sell |
8,586
-2,177
| -20% | -$256K | 0.05% | 115 |
|
|
2024
Q3 | $1.39M | Buy |
10,763
+674
| +7% | +$87.9K | 0.08% | 91 |
|
|
2024
Q2 | $1.14M | Buy |
10,089
+4,285
| +74% | +$459K | 0.09% | 91 |
|
|
2024
Q1 | $770K | Buy |
5,804
+3,142
| +118% | +$410K | 0.07% | 113 |
|
|
2023
Q4 | $325K | Buy |
+2,662
| New | +$204K | 0.03% | 160 |
|
|
2022
Q2 | – | Sell |
-7,615
| Closed | -$2.39M | – | 199 |
|
|
2022
Q1 | $2.39M | Buy |
7,615
+5,847
| +331% | +$2.2M | 0.31% | 52 |
|
|
2021
Q4 | $1.27M | Buy |
1,768
+1,298
| +276% | +$1.24M | 0.15% | 76 |
|
|
2021
Q3 | $519K | Buy |
470
+29
| +7% | +$35.6K | 0.07% | 119 |
|
|
2021
Q2 | $662K | Buy |
441
+20
| +5% | +$27.7K | 0.09% | 98 |
|
|
2021
Q1 | $664K | Sell |
421
-61
| -13% | -$143K | 0.11% | 93 |
|
|
2020
Q4 | $968K | Sell |
482
-227
| -32% | -$362K | 0.17% | 72 |
|
|
2020
Q3 | $871K | Sell |
709
-49
| -6% | -$56.2K | 0.2% | 66 |
|
|
2020
Q2 | $900K | Buy |
758
+304
| +67% | +$264K | 0.22% | 63 |
|
|
2020
Q1 | $204K | Sell |
454
-1,176
| -72% | -$1.07M | 0.07% | 114 |
|
|
2019
Q4 | $1.87M | Buy |
1,630
+609
| +60% | +$546K | 0.5% | 45 |
|
|
2019
Q3 | $631K | Buy |
1,021
+305
| +43% | +$253K | 0.2% | 88 |
|
|
2019
Q2 | $729K | Buy |
716
+130
| +22% | +$126K | 0.24% | 76 |
|
|
2019
Q1 | $702K | Buy |
586
+21
| +4% | +$21.8K | 0.24% | 72 |
|
|
2018
Q4 | $371K | Buy |
565
+296
| +110% | +$310K | 0.15% | 94 |
|
|
2018
Q3 | $501K | Sell |
269
-5
| -2% | -$9.82K | 0.16% | 88 |
|
|
2018
Q2 | $535K | Buy |
+274
| New | +$483K | 0.2% | 81 |
|
|
2018
Q1 | – | Sell |
-497
| Closed | -$773K | – | 184 |
|
|
2017
Q4 | $773K | Sell |
497
-297
| -37% | -$455K | 0.33% | 60 |
|
|
2017
Q3 | $1.33M | Sell |
794
-130
| -14% | -$180K | 0.63% | 38 |
|
|
2017
Q2 | $1.22M | Buy |
924
+605
| +190% | +$610K | 0.6% | 36 |
|
|
2017
Q1 | $322K | Sell |
319
-3,652
| -92% | -$3.25M | 0.18% | 106 |
|
|
2016
Q4 | $2.85M | Buy |
3,971
+1,129
| +40% | +$848K | 1.89% | 10 |
|
|
2016
Q3 | $1.91M | Buy |
2,842
+457
| +19% | +$377K | 1.35% | 18 |
|
|
2016
Q2 | $1.42M | Buy |
2,385
+1,778
| +293% | +$1.11M | 1.11% | 21 |
|
|
2016
Q1 | $332K | Sell |
607
-76
| -11% | -$48.1K | 0.26% | 80 |
|
|
2015
Q4 | $1.15M | Buy |
+683
| New | +$1.11M | 0.83% | 28 |
|
Other funds holding LABU
GS
TRCT
EFG
Traynor Capital Management's LABU Position: Q1 2025 in Review
Traynor Capital Management sold out of Direxion Daily S&P Biotech Bull 3X ETF (LABU) in Q1 2025, closing a stake of 8,586 shares — an estimated $773K sold.
Traynor Capital Management first reported a position in LABU in Q4 2015 and held it in 30 quarters. The position peaked at $2.85M in Q4 2016. 34 funds tracked by Wall St. Rank hold LABU as of Q1 2025.
- Traynor Capital Management reported no remaining Direxion Daily S&P Biotech Bull 3X ETF position as of Q1 2025 after selling out during the quarter.
- Traynor Capital Management sold 8,586 Direxion Daily S&P Biotech Bull 3X ETF shares in Q1 2025, an estimated $773K.
- Traynor Capital Management first reported a position in Direxion Daily S&P Biotech Bull 3X ETF in Q4 2015 and held it in 30 quarters.
- Traynor Capital Management's Direxion Daily S&P Biotech Bull 3X ETF position peaked at $2.85M in Q4 2016.
- 34 funds tracked by Wall St. Rank held Direxion Daily S&P Biotech Bull 3X ETF as of Q1 2025.
Based on Traynor Capital Management's 13F filing for Q1 2025, filed 12 May 2025.